| Literature DB >> 26649135 |
J Kabzinski1, B Mucha1, M Cuchra1, L Markiewicz1, K Przybylowska1, A Dziki2, L Dziki2, I Majsterek1.
Abstract
DNA oxidative lesions are widely considered as a potential risk factor for colorectal cancer development. The aim of this work was to determine the role of the efficiency of base excision repair, both in lymphocytes and in epithelial tissue, in patients with CRC and healthy subjects. SNPs were identified within genes responsible for steps following glycosylase action in BER, and patients and healthy subjects were genotyped. A radioisotopic BER assay was used for assessing repair efficiency and TaqMan for genotyping. Decreased BER activity was observed in lymphocyte extract from CRC patients and in cancer tissue extract, compared to healthy subjects. In addition, polymorphisms of EXO1, LIG3, and PolB may modulate the risk of colorectal cancer by decreasing (PolB) or increasing (LIG3 and EXO1) the chance of malignant transformation.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26649135 PMCID: PMC4663340 DOI: 10.1155/2016/3125989
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
The refSNP and thermal conditions used in the PCR reaction.
| Gene |
|
|
|
|---|---|---|---|
| Polymorphism | 242Pro/Arg | 780Arg/His | 589Lys/Glu |
|
| |||
| refSNP | 3136797 | 3136025 | 1047840 |
|
| |||
| Thermal conditions | (1) 95°C—10 min | ||
| (2) 92°C—15 sec | |||
| (3) 60°C—1 min | |||
| (4) Step 2 and 3—45x | |||
|
| |||
| Dyes | ROX, HEX, and FAM | ||
|
| |||
| Ref. dye | ROX | ||
Figure 1(I) A uracil-containing oligonucleotide was subjected to action of polynucleotide kinase to attach a radioactive phosphate group from [γ-32P] ATP. It was hybridized with a second oligonucleotide whose sequence was adjusted to obtain sticky ends referring to XhoI and XbaI digestion site. (II) The short DNA fragment prepared in stage I was cloned into a pBluescriptII plasmid. (III) Uracil-DNA glycosylase was utilized to remove uracil and, as consequence, create a single gap in DNA to act as a synthetic lesion. (IV) A plasmid with single AP site constituted a substrate for the protein extract in 90-minute repair incubation. (V) Two SacI recognition sites of the pBluescriptII plasmid were used to excise 450 pb-long fragment covering the lesion site and radioactive label for analysis on 8% urea/acrylamide gel. (VI) Interpretation of outcomes was based on detection of two bands. The full-length 450 pb fragment reflects restored DNA fraction, whereas presence of short 180 pb fraction indicates the amount of unrepaired DNA. U: uracil; AP: apurinic/apyrimidinic.
The distribution of genotypes, allele frequencies, and the analysis of the odds ratio (OR) for 589Lys/Glu polymorphism of EXO1 gene in patients with colorectal cancer (CRC) and the control group.
| Genotype/allele | Patients | Controls | OR (95% CI) |
|
|---|---|---|---|---|
| Lys/Lys | 57 | 69 | 1 (ref.) | — |
| Lys/Glu |
|
|
|
|
| Glu/Glu | 49 | 88 | 0.674 (0.411–1.106) | 0.118 |
| Lys | 317 | 285 | 1 (ref.) | — |
| Glu | 301 | 323 | 0.838 (0.670–1.048) | 0.121 |
Genotype distribution in Hardy-Weinberg equilibrium; χ 2 = 0.612.
The distribution of genotypes, allele frequencies, and the analysis of the odds ratio (OR) for 242Pro/Arg polymorphism of PolB gene in patients with colorectal cancer (CRC) and the control group.
| Genotype/allele | Patients | Controls | OR (95% CI) |
|
|---|---|---|---|---|
| Pro/Pro | 147 | 121 | 1 (ref.) | — |
| Pro/Arg | 123 | 142 | 0.713 (0.507–1.003) | 0.052 |
| Arg/Arg | 33 | 39 | 0.697 (0.413–1.174) | 0.174 |
| Pro | 417 | 384 | 1 (ref.) | — |
| Arg |
|
|
|
|
Genotype distribution in Hardy-Weinberg equilibrium; χ 2 = 0.791.
The distribution of genotypes, allele frequencies, and the analysis of the odds ratio (OR) for 780Arg/His polymorphism of LIG3 gene in patients with colorectal cancer (CRC) and the control group.
| Genotype/allele | Patients | Controls | OR (95% CI) |
|
|---|---|---|---|---|
| Arg/Arg | 101 | 121 | 1 (ref.) | — |
| Arg/His |
|
|
|
|
| His/His | 36 | 52 | 0.829 (0.503–1.368) | 0.462 |
| Arg | 375 | 374 | 1 (ref.) | — |
| His | 245 | 236 | 1.035 (0.823–1.302) | 0.764 |
Genotype distribution in Hardy-Weinberg equilibrium; χ 2 = 0.125.
The distribution of genotypes and the analysis of the odds ratio (OR) for gene-gene interactions: 589Lys/Glu EXO1 and 242Pro/Arg PolB in patients with colorectal cancer (CRC) and the control group.
| Genotype | Patients | Controls | OR (95% CI) |
|
|---|---|---|---|---|
| Lys/Lys-Pro/Pro | 24 | 28 | 1 (ref.) | — |
| Lys/Lys-Pro/Arg | 20 | 26 | 0.897 (0.404–1.994) | 0.791 |
| Lys/Lys-Arg/Arg | 11 | 15 | 0.856 (0.331–2.212) | 0.752 |
| Lys/Glu-Pro/Pro |
|
|
|
|
| Lys/Glu-Pro/Arg | 81 | 72 | 1.313 (0.698–2.467) | 0.396 |
| Lys/Glu-Arg/Arg | 19 | 23 | 0.964 (0.426–2.180) | 0.920 |
| Glu/Glu-Pro/Pro | 23 | 42 | 0.639 (0.303–1.346) | 0.238 |
| Glu/Glu-Pro/Arg | 22 | 44 | 0.583 (0.276–1.232) | 0.156 |
| Glu/Glu-Arg/Arg | 3 | 1 | — | — |
The distribution of genotypes and the analysis of the odds ratio (OR) for gene-gene interactions: 589Lys/Glu EXO1 and 780Arg/His LIG3 in patients with colorectal cancer (CRC) and the control group.
| Genotype | Patients | Controls | OR (95% CI) |
|
|---|---|---|---|---|
| Lys/Lys-Arg/Arg | 21 | 27 | 1 (ref.) | — |
| Lys/Lys-Arg/His | 31 | 27 | 1.476 (0.684–3.185) | 0.320 |
| Lys/Lys-His/His | 3 | 15 | — | — |
| Lys/Glu-Arg/Arg | 64 | 46 | 1.789 (0.902–3.547) | 0.094 |
| Lys/Glu-Arg/His |
|
|
|
|
| Lys/Glu-His/His | 17 | 23 | 0.950 (0.407–2.218) | 0.920 |
| Glu/Glu-Arg/Arg |
|
|
|
|
| Glu/Glu-Arg/His | 18 | 26 | 0.890 (0.389–2.038) | 0.777 |
| Glu/Glu-His/His | 15 | 13 | 1.484 (0.582–3.784) | 0.409 |
The distribution of genotypes and the analysis of the odds ratio (OR) for gene-gene interactions: 242Pro/Arg PolB and 780Arg/His LIG3 in patients with colorectal cancer (CRC) and the control group.
| Genotype | Patients | Controls | OR (95% CI) |
|
|---|---|---|---|---|
| Pro/Pro-Arg/Arg | 52 | 56 | 1 (ref.) | — |
| Pro/Pro-Arg/His |
|
|
|
|
| Pro/Pro-His/His | 12 | 24 | 0.539 (0.245–1.185) | 0.121 |
| Pro/Arg-Arg/Arg | 38 | 48 | 0.853 (0.483–1.506) | 0.584 |
| Pro/Arg-Arg/His | 66 | 73 | 0.974 (0.589–1.611) | 0.920 |
| Pro/Arg-His/His | 19 | 21 | 0.974 (0.471–2.015) | 1.000 |
| Arg/Arg-Arg/Arg | 9 | 15 | 0.646 (0.261–1.603) | 0.343 |
| Arg/Arg-Arg/His | 20 | 17 | 1.267 (0.599–2.679) | 0.538 |
| Arg/Arg-His/His | 4 | 7 | — | — |
Figure 2A comparison of BER activity in the lymphocytes and tissue of CRC patients and healthy controls. Each electropherogram shows two fractions of DNA: 450 pb repaired and 185 pb unrepaired. Lanes 1-2 indicate lymphocyte BER efficiency while lanes 3-4 refer to BER in tissue. Samples are presented in the following order: K: positive control; DNA substrate did not contain uracil and so reflects 100% of repair; 1: healthy control; 2: colorectal cancer; 3: unchanged colon tissue; 4: colorectal cancer.